Clinical Trials Logo

Pituitary Adenomas clinical trials

View clinical trials related to Pituitary Adenomas.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04244708 Not yet recruiting - Pituitary Adenomas Clinical Trials

The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas

Start date: February 10, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study was to determine whether radiotherapy combined with Temozolomide is more effective than radiotherapy alone in the treatment of patients with refractory pituitary adenomas. The Basic treatment was Radiotherapy over a period of six weeks, for a total dose of 54 Gy. The150 participants were randomized to use either radiotherapy plus Temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), or radiotherapy plus placebo for 6 weeks. After a 4-week break, followed by six cycles of placebo or adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle). The primary end point was Objective Response rate, the second end point was PFS. Greater response was anticipated in patients treated with Temozolomide+ radiotherapy than radiotherapy alone.